Novel approaches to develop community-built biological network models for potential drug discovery


Authored by  M Talikka, N Bukharov, WS Hayes, M Hofmann-Apitius*, L Alexopoulos*, M Peitsch, J Hoeng

Published in Expert Opinion on Drug Discovery     Volume 12, Issue 8
* This author is not affiliated with PMI.
ABSTRACT

Introduction: Hundreds of thousands of data points are now routinely generated in clinical trials by molecular profiling and NGS technologies. A true translation of this data into knowledge is not possible without analysis and interpretation in a well-defined biology context. Currently, there are many public and commercial pathway tools and network models that can facilitate such analysis. At the same time, insights and knowledge that can be gained is highly dependent on the underlying biological content of these resources. Crowdsourcing can be employed to guarantee the accuracy and transparency of the biological content underlining the tools used to interpret rich molecular data.

Areas covered: In this review, the authors describe crowdsourcing in drug discovery. The focal point is the efforts that have successfully used the crowdsourcing approach to verify and augment pathway tools and biological network models. Technologies that enable the building of biological networks with the community are also described.

Expert opinion: A crowd of experts can be leveraged for the entire development process of biological network models, from ontologies to the evaluation of their mechanistic completeness. The ultimate goal is to facilitate biomarker discovery and personalized medicine by mechanistically explaining patients’ differences with respect to disease prevention, diagnosis, and therapy outcome.